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Abstract
Background  One  of  the  first  investigations  concerning 
extracorporeal  treatment  of  hypercholesterolemia  was 
performed in 1967 by plasma exchange in patients with 
homozygous or severe heterozygous familial hypercholes-
terolemia (FH). In the following decades, several specific 
lipid apheresis systems were developed to efficiently elimi-
nate low-density lipoprotein (LDL) cholesterol and Lp(a) 
cholesterol in hypercholesterolemic patients. In the early 
1980s, the main clinical indication has been homozygous 
FH  including  mainly  children  and  pregnant  women.  In 
consideration of the current development of lipid-lowering 
regimens and scientific knowledge of preventing progres-
sion  of  cardiovascular  diseases,  the  spectrum  of  indica-
tions to initiate lipid apheresis was extended due to still 
insufficient lipid-lowering therapy in some clinical cases. 
However, a generally accepted indication for lipid apher-
esis  treatment  is  still  under  discussion.  In  Germany,  the 
target-oriented distribution of increasingly limited health-
care resources demand data which support the benefit of 
established  treatment  procedures  such  as  lipid  apheresis. 
In  recent  years,  the  Federal  Joint  Committee  (G-BA), 
a paramount decision-making body of the German Health-
care System, issued to reassess the approval of chronic lip-
id apheresis therapy for regular reimbursement. Therefore, 
in 2005, an interdisciplinary German Apheresis Working 
Group has been established by members of both the Ger-
man societies of nephrology. One of the first goals of this 
working group was a revision of the indications for lipid 
apheresis corresponding to current guidelines and recom-
mendations for the treatment of lipid disorders. In addition, 
recently new pathophysiological perceptions of the impact 
of lipoproteins on atherogenesis and thrombosis were also 
considered.
Methods and Results  Since 2005, the working group met 
on a regular basis to substantiate the first defined goals. 
The indications for lipid apheresis were critically revised 
with respect to actual results from clinical investigations, 
cardiovascular  guidelines,  and  scientific  knowledge  and 
were accepted by the members of the apheresis working 
group.
Conclusions  There is consensus between the medical soci-
eties and health insurance funds regarding the need for gen-
eral accepted guidelines for lipid apheresis. Recommenda-
tions for the indications of lipid apheresis were developed, 
but additionally these results should be confirmed by medi-
cal societies to transform them to guidelines. However, due 
to limited data showing that lipid apheresis has effects on 
the progression of cardiovascular diseases all members of 
the apheresis working group support a project for creating 
a lipid apheresis registry. This apheresis registry has been 
developed and recently started. The primary goal is to sub-
stantiate prospective long-term data on clinical outcome of 
chronic lipid apheresis treatment and to support additional 
clinical research activities in this field. In addition, this reg-
istry should comply with the actual requests of the Federal 
Joint Committee (G-BA).
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Introduction
First investigations dealing with extracorporeal treatment 
of hypercholesterolemia were performed in 1967 by plasma 
exchange [1]. During the following decades, more specific 
lipid apheresis systems were developed to efficiently elimi-
nate low-density lipoprotein (LDL) cholesterol and Lp(a) 
by adsorption, precipitation, and specific filtration technique 
[2–12].
Therefore, the currently established lipid apheresis sys-
tems are effective extracorporeal lipid-lowering treatment 
procedures for selected patients suffering from progressive 
cardiovascular diseases induced by severe hyperlipidemia, 
in particular hypercholesterolemia and Lp(a) hyperlipopro-
teinemia [13].
In the early 1980s, the main clinical indication for lipid 
apheresis has been focused on homozygous familial hyper-
cholesterolemia (FH) including mainly children and preg-
nant women [13]. Because of a better understanding of the 
correlation between high LDL cholesterol and Lp(a) choles-
terol concentrations and an obvious progression of cardio-
vascular diseases, the demand of effective lipid reduction 
was increased [14, 15]. In recent years, well-designed inves-
tigations with hypercholesterolemic patients suffering from 
coronary  heart  disease  (CHD)  showed  a  better  survival, 
when LDL cholesterol was efficiently decreased [16]. The-
refore, new lipid thresholds were defined in hypercholeste-
rolemic patients suffering from progressive cardiovascular 
diseases, which include a clear recommendation to initiate 
treatment with lipid-lowering drugs [17, 18]. Against the 
background of the current development of lipid-lowering 
regimens  and  the  knowledge  that  progression  of  cardio-
vascular diseases can be prevented by adequate therapeu-
tic means, the spectrum for lipid apheresis indications was 
extended to severe clinical cases, in which lipid-lowering 
drug therapy is insufficient or severe drug-associated side 
effects have occurred.
Unfortunately, the systematic investigations concerning 
the beneficial effects of lipid apheresis treatment such as a 
randomized double-blinded prospective lipid lowering study 
with significant statistical power are still lacking worldwide 
and are now difficult to perform [19] due to ethical reasons 
against the evidence from the current scientific knowledge. 
Therefore, in the last two decades, the indications for lipid 
apheresis treatment remained vague [20].
The Federal Joint Committee’s (G-BA) assessment of 
medical treatments and procedures follows a standardized 
procedure  which  rests  on  evidence-based  medicine.  The 
generally accepted current state of medical knowledge is 
ascertained for the purpose of assessing the effectiveness, 
quality, and economic efficiency of the diagnostic and the-
rapeutic methods under examination.
In 2003, the German reimbursement guidelines for lipid-
apheresis were again revised by G-BA confirming the rele-
vance of LDL cholesterol but denying an important role of 
Lp(a) cholesterol to establish the indication for lipid aphe-
resis. Comments published with that decision prompted all 
medical disciplines, in particular nephrologists, to continue 
the  critical  discussion  of  chronic  lipid  apheresis  therapy 
and to develop guidelines with broad acceptance within all 
related medical disciplines. To focus these discussions, an 
interdisciplinary German Apheresis Working Group (AWG) 
was founded in 2005 by members of both German socie-
ties of nephrology (Deutsche Gesellschaft für Nephrologie 
(DGfN), Verband Deutsche Nierenzentren (VDN)) with the 
goals to be a partner in the dialogue and negotiations with 
the G-BA and to standardize the indications for lipid aphe-
resis [21].
Until now, the indications for lipid apheresis treatment 
were critically revised and adapted by AWG to substantiate 
benefit and cost-effectiveness of established lipid-lowering 
treatment procedures and to optimize lipid-lowering therapy 
through  lipid  apheresis  treatment  considering  the  increa-
singly limited healthcare resources [21].
Most members were previously members of an apheresis 
working group, which consisted of nephrologists, cardiolo-
gists, endocrinologists, and specialists of clinical chemistry 
and laboratory medicine [22].
Methods and results
From 2005 until today, several meetings were held and the 
suggestions from actual publications as well as recommen-
dations from national and international cardiovascular soci-
eties were critically discussed. At the end of all discussions, 
all attendees agreed on the following consensus statements:
Recommendations for maximal lipid-lowering therapy 
in patients suffering from severe hyperlipidemia
All patients suffering from high LDL cholesterol concen-
trations  according  to  actual  guidelines,  with  triglyceride 
less than 300 mg/dl and without any evidence for remnant 
hyperlipidemia or chylomicronemia, should be considered 
for long term lipid-lowering therapy.
However, before lipid-lowering drug therapy should be 
considered, a basic diet with low cholesterol and rich in 
omega-3 fatty acids is advised for these patients, correspon-
ding to the recommendations of EAS and NCEP.1 3
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When lifestyle modification with an emphasis on normal-
ization of body weight and heart-healthy patterns of dietary 
intake and physical activity fails in hyperlipidemic patients, 
the  lipid-lowering  drug  regimens  should  be  recommen-
ded. It should be taken into account that the lipid-lowering 
success in these recommendations depends on attention to 
multiple  tasks  like  titration  of  medications,  management 
of  side  effects,  careful  use  of  combination  lipid-altering 
drug therapies. Side effects associated with lipid lowering 
drugs or their combinations should be well documented and 
reported to the Drug Commission of the German Medical 
Association.
The initiation of a lipid apheresis treatment should be 
considered within a period of 3 months, when diet and lipid-
lowering drug procedures remained ineffective (conserva-
tive therapy) to LDL cholesterol or Lp(a) cholesterol levels 
in the following situations:
•    In primary prevention, the patients suffering from fami-
lial  hypercholesterolemia  with  remaining  LDL  cho-
lesterol  concentrations  > 160  mg/dl  (4.2  mmol/l)  and 
cardiovascular events in close relatives.
•    In  secondary  prevention,  the  patients  suffering  from 
progressive  cardiovascular  events  with  remaining 
LDL  cholesterol  concentrations  > 120–130  mg/dl 
(3.1–3.4 mmol/l).
•    In  addition,  independent  of  LDL  cholesterol  concen-
trations, the patients suffering from progressive cardio-
vascular disease clinically assessed or by using imaging 
techniques  with  lipoprotein  a  (Lp(a))  concentrations 
> 60 mg/dl.
These regulations may be flexibly applied with respect to 
individual clinical conditions of the affected patients. When 
progressive cardiovascular events occurred despite maxi-
mal conservative therapy, earlier initiation of chronic lipid 
apheresis should be considered.
According  to  the  Federal  Joint  Committee’s  (G-BA) 
assessment of medical treatments and procedures, the lipid 
apheresis can only be performed in Germany although the 
indication  for  lipid  apheresis  is  given,  if  the  additional 
administrative standardized procedures are completed. In 
compliance with the given G-BA guidelines, only specia-
lists in vascular medicine like cardiologists, specialists in 
lipidology, and neurologists can consider the indication for 
lipid  apheresis. Together  with  the  patient’s  approval  and 
expert opinion, all nephrologists must file their applications 
to an apheresis subcommittee of the Associations of Statut-
ory Health Insurance Physicians (Kassenärztliche Vereini-
gungen; ASHIPs). Only after an agreement of this apheresis 
subcommittee, the lipid apheresis treatment can be perfor-
med for one year. However, within a year, the application 
procedures for lipid apheresis must be repeated in the way 
mentioned above [23, 24].
Discussion
Since 1967, the lipid apheresis treatments were performed 
in patients with severe familial hypercholesterolemia and 
cardiovascular diseases. During the following years, speci-
fic lipid apheresis regimens were developed and were able 
to decrease LDL cholesterol for more than 60% or Lp(a) 
cholesterol for more than 55%, respectively [25]. Howe-
ver, general accepted guidelines for lipid apheresis are still 
lacking.
There is consensus between the medical societies and 
health insurance authorities regarding the need for generally 
accepted guidelines for lipid apheresis [19].
During the past 10 years, several review articles from 
different countries have discussed the indications for using 
lipid apheresis to treat refractory hypercholesterolemia in 
association with severe progressive cardiovascular damage 
[13, 22, 26, 27]. In addition, definitive recommendations 
have been published by various national as well as inter-
national societies and organizations [28–31].
The Food and Drug Administration (FDA) has appro-
ved the use of dextran sulfate-cellulose adsorption (DSA) 
and  Heparin-induced  extracorporeal  LDL  precipitation 
(HELP) apheresis system in three categories of patients in 
the US: Functional FH homozygotes, with LDL cholesterol 
> 500 mg/dl (13 mmol/l); functional FH heterozygotes, with 
LDL cholesterol > 300 mg/dl (7.8 mmol/l); and functional 
FH heterozygotes with documented CHD and LDL choles-
terol > 200 mg/dl (5.2 mmol/l) [32].
However, all former reviews have shown that there is a 
gap between the demand for aggressive LDL cholesterol 
lowering (< 100 mg/dl (2.6 mmol/l), in some cases < 70 mg/
dl (1.8 mmol/l)), when cardiovascular damage had occurred 
in a hypercholesterolemic patient and the consequent appli-
cation of lipid lowering therapies like diet, lipid-lowering 
drugs, and in special clinical cases lipid apheresis [24].
Now, recommendations for the indications of lipid aphe-
resis were developed for Germany by the members of the 
German Apheresis Working Group (AWG), but additionally 
these results should be confirmed by medical societies con-
densing them to guidelines [24].
All members of the AWG agreed that the indications of 
lipid apheresis should be critically reviewed within one year 
and adapted to new scientific recommendations, findings, or 
drug developments.
Under  actual  consideration  is  an  investigation,  which 
identified LPA variants (LPA locus on 6q26–27) encoding 
Lp(a) lipoprotein that were strongly associated with both an 
increased level of Lp(a) lipoprotein and an increased risk of 
coronary disease [33], but these results need further inves-
tigations to substantiate this method as a tool to determine 
high-risk patients for Lp(a) associated cardiovascular disea-
ses and consequently for lipid apheresis treatment. Further-1 3
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more, a new developed antisense apolipoprotein B synthesis 
inhibitor may become an additional potent agent in lipid-
lowering therapy [34]. However, long-term clinical data are 
still lacking.
Due  to  limited  data  showing  that  lipid  apheresis  has 
effects  on  the  progression  of  cardiovascular  disease,  all 
members of AWG support a project for establishing a lipid 
apheresis registry [21].
A registry represents an appropriate instrument for qua-
lity management of extracorporeal treatment. Worldwide, 
several registries exist with different purposes. The world 
apheresis registry, the Swedish, French, and the Canadian 
apheresis registry provide an overview of various techni-
ques of therapeutic apheresis and their clinical applications, 
which for Germany is still lacking [35–37].
A  German  apheresis  registry  was  recently  developed 
and started. The primary goal is to substantiate prospective 
long-term data on clinical outcome of chronic lipid aphe-
resis treatment and to support additional clinical research 
activities in this field.
In addition, this registry should fulfill the current require-
ments of the Federal Joint Committee (G-BA).
Conclusions
The German Apheresis Working Group (AWG) has deve-
loped actual recommendations for the indications of lipid 
apheresis treatment in consideration of current national and 
international guidelines for lipid therapeutic regimens, but 
the general acceptance in medical societies is still lacking. 
In addition, AWG designed and started a German lipid aphe-
resis registry. This registry should fulfill the requirements of 
the Federal Joint Committee (G-BA).
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